Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of JNJ-80948543 in relapsed or refractory NHL and CLL
jRCT2031240254Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of JNJ-80948543 in mature B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Waldenström macroglobulinemia (WM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with dose-limiting toxicity, Number of participants with adverse events and 1 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
JNJ-80948543
03
Conditions
mature B-cell lymphomachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on jRCT2031240254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240254.